Alaunos Therapeutics
TCRT
124 hedge funds and large institutions have $90.5M invested in Alaunos Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 21 increasing their positions, 42 reducing their positions, and 42 closing their positions.
1,963% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $491K
38% more capital invested
Capital invested by funds: $65.9M → $90.5M (+$24.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.08% less ownership
Funds ownership: 0.31% → 0.23% (-0.08%)
16% less funds holding
Funds holding: 148 → 124 (-24)
50% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 42
50% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$2.73M |
| 2 |
Millennium Management
New York
|
+$1.04M |
| 3 |
JP Morgan Chase
New York
|
+$598K |
| 4 |
E
Ergoteles
New York
|
+$597K |
| 5 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
+$541K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.31M |
| 2 |
Goldman Sachs
New York
|
-$2.78M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.77M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.04M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.1M |
TCRT Hedge Fund Activity: Q2 2022 in Review
124 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2022, worth a combined $90.5M — up 38% from $65.9M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of TCRT and 21 opened new positions — a net loss of 21 holders — while 42 trimmed existing stakes and 21 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.73M. The largest seller was BlackRock, cutting an estimated $7.31M.
- 124 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2022, down from 148 in Q1 2022.
- Funds reported $90.5M of Alaunos Therapeutics stock for Q2 2022, up 38% quarter-over-quarter.
- 21 funds opened new Alaunos Therapeutics positions in Q2 2022 and 42 closed out, a net change of -21 holders.
- The largest Alaunos Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $2.73M added.
- The largest Alaunos Therapeutics seller in Q2 2022 was BlackRock, an estimated $7.31M sold.
Based on aggregated 13F filings for Q2 2022.